Compare RYM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYM | CING |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 40.5M |
| IPO Year | 2021 | 2021 |
| Metric | RYM | CING |
|---|---|---|
| Price | $16.24 | $5.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 23.3K | ★ 398.6K |
| Earning Date | 03-20-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,303,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1338.92 | N/A |
| 52 Week Low | $13.22 | $3.20 |
| 52 Week High | $53.65 | $7.92 |
| Indicator | RYM | CING |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 52.03 |
| Support Level | $14.73 | $5.47 |
| Resistance Level | $18.75 | $7.92 |
| Average True Range (ATR) | 1.92 | 0.72 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 31.73 | 33.10 |
Rythm Inc is a USA Based company. The Company's portfolio of brands delivers well-being to millions of Americans every year. The company features some of the recognized and trusted names in the cannabis and hemp industries, including RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, &Shine, Doctor Solomon's and Good Green in thousands of physical locations and online channels. With products rooted in quality, safety, and innovation, the Company is shaping cannabis experiences that enhance daily life.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.